PMID- 29952495 OWN - NLM STAT- MEDLINE DCOM- 20180816 LR - 20180816 IS - 0342-9601 (Print) IS - 0342-9601 (Linking) VI - 40 IP - 2 DP - 2017 Feb CTI - Breast Cancer Reviews TI - Breast cancer: basics, screening, diagnostics and treatment. PG - 55-64 AB - Breast cancer is by far the most common malignancy in women. The median age is 64 years. Stage at diagnosis and biological features determine the prognosis. Patients with early breast cancer, with locally advanced disease and with locoregional relapse can be cured. Modern treatment is multimodal. It includes surgery, radiation and drug therapy. Patients with metastatic disease are treated with palliative intent. Aims are alleviation of symptoms and prolongation of survival. Breast cancer specific mortality has continually decreased in the past 10 years. Five year survival rate is 87% in Germany. Patients with early breast cancer have an even higher chance of cure. FAU - Wörmann, Bernhard AU - Wörmann B AD - Medizinische Klinik mit Schwerpunkt Hämatologie LA - eng LA - ger PT - Journal Article PT - Review TT - Grundlagen, Früherkennung, Diagnostik und Therapie. PL - Germany TA - Med Monatsschr Pharm JT - Medizinische Monatsschrift fur Pharmazeuten JID - 7802665 RN - 0 (Antineoplastic Agents) SB - IM MH - Combined Modality Therapy MH - Early Detection of Cancer MH - Female MH - Humans MH - Mass Screening EDAT- 2017/02/01 00:00 MHDA- 2018/08/17 06:00 CRDT- 2018/06/29 06:00 PHST- 2018/06/29 06:00 [entrez] PHST- 2017/02/01 00:00 [pubmed] PHST- 2018/08/17 06:00 [medline] PST - ppublish SO - Med Monatsschr Pharm. 2017 Feb;40(2):55-64. GN - KIE: Article and commentaries GN - KIE: KIE BoB Subject Heading: health care PMID- 28298516 OWN - NLM STAT- MEDLINE DCOM- 20171023 LR - 20171023 IS - 1943-5657 (Electronic) IS - 0033-8397 (Linking) VI - 88 IP - 4 DP - 2017 Mar TI - Precision Medicine in Breast Cancer. CTI - Breast Cancer Reviews PG - 401M-421M AB - Breast cancer care has improved markedly in recent decades, but new advancements in diagnosis and treatment depend on translating genomics and precision medicine into clinical care. This article discusses the basics of genomics, breast cancer biomarkers and subtypes, and the effects of genomic advancements on future breast cancer diagnosis, treatment, and survival. The article also presents challenges related to introducing precision medicine into cancer care and the role of imaging in breast cancer diagnosis and treatment in precision medicine. CI - ©2017 American Society of Radiologic Technologists. FAU - Odle, Teresa G AU - Odle TG LA - eng PT - Journal Article PT - Review PL - United States TA - Radiol Technol JT - Radiologic technology JID - 0401256 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor MH - Breast Neoplasms/*diagnosis/*genetics/*therapy MH - Female MH - *Genomics MH - Humans MH - *Precision Medicine EDAT- 2017/03/17 06:00 MHDA- 2017/10/24 06:00 CRDT- 2017/03/17 06:00 PHST- 2017/03/17 06:00 [entrez] PHST- 2017/03/17 06:00 [pubmed] PHST- 2017/10/24 06:00 [medline] AID - 88/4/401M [pii] PST - ppublish SO - Radiol Technol. 2017 Mar;88(4):401M-421M. GN - KIE: Article and commentaries PMID- 20521754 OWN - NLM STAT- MEDLINE DCOM- 20100622 LR - 20110420 IS - 1532-0650 (Electronic) IS - 0002-838X (Linking) VI - 81 IP - 11 DP - 2010 Jun 1 TI - Treatment of breast cancer. PG - 1339-46 AB - Understanding breast cancer treatment options can help family physicians care for their patients during and after cancer treatment. This article reviews typical treatments based on stage, histology, and biomarkers. Lobular carcinoma in situ does not require treatment. Ductal carcinoma in situ can progress to invasive cancer and is treated with breast-conserving surgery and radiation therapy without further lymph node exploration or systemic therapy. Stages I and II breast cancers are usually treated with breast-conserving surgery and radiation therapy. Radiation therapy following breast-conserving surgery decreases mortality and recurrence. Sentinel lymph node biopsy is considered for most breast cancers with clinically negative axillary lymph nodes, and it does not have the adverse effects of arm swelling and pain that are associated with axillary lymph node dissection. Choice of adjuvant systemic therapy depends on lymph node involvement, hormone receptor status, ERBB2 (formerly HER2 or HER2/neu) overexpression, and patient age and menopausal status. In general, node-positive breast cancer is treated systemically with chemotherapy, endocrine therapy (for hormone receptor-positive cancer), and trastuzumab (for cancer overexpressing ERBB2). Anthracycline- and taxane-containing chemotherapeutic regimens are active against breast cancer. Stage III breast cancer typically requires induction chemotherapy to downsize the tumor to facilitate breast-conserving surgery. Inflammatory breast cancer, although considered stage III, is aggressive and requires induction chemotherapy followed by mastectomy, rather than breastconserving surgery, as well as axillary lymph node dissection and chest wall radiation. Prognosis is poor in women with recurrent or metastatic (stage IV) breast cancer, and treatment options must balance benefits in length of life and reduced pain against harms from treatment. FAU - Maughan, Karen L AU - Maughan KL AD - Department of Family Medicine, University of Virginia School of Medicine, Charlottesville, VA 22908, USA. kmaughan@virginia.edu FAU - Lutterbie, Mark A AU - Lutterbie MA FAU - Ham, Peter S AU - Ham PS LA - eng PT - Introductory Journal Article PL - United States TA - Am Fam Physician JT - American family physician JID - 1272646 RN - 0 (Antineoplastic Agents) SB - AIM SB - IM CIN - Am Fam Physician. 2010 Jun 1;81(11):1330-2. PMID: 20521750 CIN - Am Fam Physician. 2010 Jun 1;81(11):1347-9. PMID: 20527363 CIN - Am Fam Physician. 2011 Mar 1;83(5):502-6; author reply 507. PMID: 21391514 CIN - Am Fam Physician. 2011 Mar 1;83(5):507; author reply 507. PMID: 21391515 MH - Antineoplastic Agents/therapeutic use MH - Breast Neoplasms/drug therapy/pathology/radiotherapy/surgery/*therapy MH - Combined Modality Therapy MH - Female MH - Humans MH - Mastectomy MH - Neoplasm Staging MH - Sentinel Lymph Node Biopsy RF - 63 EDAT- 2010/06/05 06:00 MHDA- 2010/06/23 06:00 CRDT- 2010/06/05 06:00 PHST- 2010/06/05 06:00 [entrez] PHST- 2010/06/05 06:00 [pubmed] PHST- 2010/06/23 06:00 [medline] AID - d8230 [pii] PST - ppublish SO - Am Fam Physician. 2010 Jun 1;81(11):1339-46. PMID- 27533387 OWN - NLM STAT- MEDLINE DCOM- 20170714 LR - 20170714 IS - 2047-9018 (Electronic) IS - 0029-6570 (Linking) VI - 30 IP - 51 DP - 2000 Nov-Dec TI - Title that spans multiple lines for this particular research article PG - 15 LID - 10.7748/ns.30.51.15.s16 [doi] AB - Essential facts Breast cancer is the most common cancer in the UK, with around 60,000 new cases diagnosed each year, according to the charity Breast Cancer Care. Over a lifetime, women have a one in eight risk of developing it. FAU - Pearce, Lynne AU - Pearce L LA - eng PT - Journal Article PL - England TA - Nurs Stand JT - Nursing standard (Royal College of Nursing (Great Britain) : 1987) JID - 9012906 SB - N MH - Breast Neoplasms/*diagnosis/epidemiology/*physiopathology MH - Female MH - Humans MH - Risk Factors MH - United Kingdom/epidemiology EDAT- 2016/08/18 06:00 MHDA- 2017/07/15 06:00 CRDT- 2016/08/18 06:00 PHST- 2016/08/18 06:00 [entrez] PHST- 2016/08/18 06:00 [pubmed] PHST- 2017/07/15 06:00 [medline] AID - 10.7748/ns.30.51.15.s16 [doi] PST - ppublish SO - Nurs Stand. 2016 Aug 17;30(51):15. doi: 10.7748/ns.30.51.15.s16. PMID- 29284222 OWN - NLM STAT- MEDLINE DCOM- 20180105 LR - 20180105 IS - 1898-2263 (Electronic) IS - 1232-1966 (Linking) VI - 24 IP - 4 DP - 2017 Dec 23 TI - Primary and secondary prevention of breast cancer. PG - 549-553 LID - 75943 [pii] LID - 10.26444/aaem/75943 [doi] AB - INTRODUCTION: Breast cancer is the most common cancer among women and is the second cancer frequently occurring worldwide of newly-diagnosed cancers. There is much evidence showing the influence of life style and environmental factors on the development of mammary gland cancer (high-fat diet, alcohol consumption, lack of physical exercise), the elimination of which (primary prevention) may contribute to a decrease in morbidity and mortality. Secondary prevention, comprising diagnostic tests (e.g. mammography, ultrasonography, magnetic resonance imaging, breast self-examination, as well as modern and more precise imaging methods) help the early detection of tumours or lesions predisposing to tumours. OBJECTIVE: The aim of this study paper is to review current knowledge and reports regarding primary and secondary prevention of breast cancer. STATE OF KNOWLEDGE: It is estimated that nearly 70% of malign tumours are caused by environmental factors, whereas in breast cancer this percentage reaches 90-95%. There are national programmes established in many countries to fight cancer, where both types of prevention are stressed as serving to decrease morbidity and mortality due to cancers. CONCLUSIONS: Cancer prevention is currently playing a key role in the fight against the disease. Behaviour modification, as well as greater awareness among women regarding breast cancer, may significantly contribute towards reducing the incidence of this cancer. Another important aspect is the number of women undergoing diagnostic tests, which still remains at an unsatisfactory level. FAU - Kolak, Agnieszka AU - Kolak A AD - St. John's Cancer Center, Department of Radiotherapy, Lublin, Poland. agkola@interia.pl. FAU - Kamińska, Marzena AU - Kamińska M AD - St. John's Cancer Center, Department of Oncology, Lublin, Poland. FAU - Sygit, Katarzyna AU - Sygit K AD - University of Szczecin, Faculty of Physical Education and Health Promotion, Szczecin, Poland. FAU - Budny, Agnieszka AU - Budny A AD - St. John's Cancer Center, Department of Radiotherapy, Lublin, Poland. FAU - Surdyka, Dariusz AU - Surdyka D AD - St. John's Cancer Center, Department of Radiotherapy, Lublin, Poland. FAU - Kukiełka-Budny, Bożena AU - Kukiełka-Budny B AD - St. John's Cancer Center, Department of Oncology, Lublin, Poland. FAU - Burdan, Franciszek AU - Burdan F AD - Human Anatomy Department, Medical Univeristy of Lublin, Poland. LA - eng PT - Journal Article PT - Review DEP - 20170718 PL - Poland TA - Ann Agric Environ Med JT - Annals of agricultural and environmental medicine : AAEM JID - 9500166 SB - IM MH - Breast Neoplasms/diagnosis/epidemiology/*prevention & control/psychology MH - Female MH - Humans MH - Life Style MH - Secondary Prevention OTO - NOTNLM OT - breast cancer OT - life style OT - mammography OT - modern diagnostics methods OT - primary and secondary prevention OT - risk factors EDAT- 2017/12/30 06:00 MHDA- 2018/01/06 06:00 CRDT- 2017/12/30 06:00 PHST- 2017/12/30 06:00 [entrez] PHST- 2017/12/30 06:00 [pubmed] PHST- 2018/01/06 06:00 [medline] AID - 75943 [pii] AID - 10.26444/aaem/75943 [doi] PST - ppublish SO - Ann Agric Environ Med. 2017 Dec 23;24(4):549-553. doi: 10.26444/aaem/75943. Epub 2017 Jul 18. PMID- 21969133 OWN - NLM STAT- MEDLINE DCOM- 20120113 LR - 20111117 IS - 1542-4863 (Electronic) IS - 0007-9235 (Linking) VI - 61 IP - 6 DP - 2011 Nov-Dec TI - Breast cancer statistics, 2011. PG - 409-18 LID - 10.3322/caac.20134 [doi] AB - In this article, the American Cancer Society provides an overview of female breast cancer statistics in the United States, including trends in incidence, mortality, survival, and screening. Approximately 230,480 new cases of invasive breast cancer and 39,520 breast cancer deaths are expected to occur among US women in 2011. Breast cancer incidence rates were stable among all racial/ethnic groups from 2004 to 2008. Breast cancer death rates have been declining since the early 1990s for all women except American Indians/Alaska Natives, among whom rates have remained stable. Disparities in breast cancer death rates are evident by state, socioeconomic status, and race/ethnicity. While significant declines in mortality rates were observed for 36 states and the District of Columbia over the past 10 years, rates for 14 states remained level. Analyses by county-level poverty rates showed that the decrease in mortality rates began later and was slower among women residing in poor areas. As a result, the highest breast cancer death rates shifted from the affluent areas to the poor areas in the early 1990s. Screening rates continue to be lower in poor women compared with non-poor women, despite much progress in increasing mammography utilization. In 2008, 51.4% of poor women had undergone a screening mammogram in the past 2 years compared with 72.8% of non-poor women. Encouraging patients aged 40 years and older to have annual mammography and a clinical breast examination is the single most important step that clinicians can take to reduce suffering and death from breast cancer. Clinicians should also ensure that patients at high risk of breast cancer are identified and offered appropriate screening and follow-up. Continued progress in the control of breast cancer will require sustained and increased efforts to provide high-quality screening, diagnosis, and treatment to all segments of the population. CI - Copyright © 2011 American Cancer Society, Inc. FAU - DeSantis, Carol AU - DeSantis C AD - Epidemiologist, Surveillance Research, American Cancer Society, Atlanta, GA 30303, USA. carol.desantis@cancer.org FAU - Siegel, Rebecca AU - Siegel R FAU - Bandi, Priti AU - Bandi P FAU - Jemal, Ahmedin AU - Jemal A LA - eng PT - Journal Article PT - Review DEP - 20111003 PL - United States TA - CA Cancer J Clin JT - CA: a cancer journal for clinicians JID - 0370647 SB - AIM SB - IM MH - Breast Neoplasms/diagnosis/economics/*epidemiology/mortality/prevention & control/therapy MH - Early Detection of Cancer/*statistics & numerical data MH - Female MH - Humans MH - Incidence MH - Mammography/*statistics & numerical data MH - Palpation MH - Poverty/*statistics & numerical data MH - Practice Guidelines as Topic MH - Risk Assessment MH - Risk Factors MH - Societies, Medical MH - Survival Rate MH - United States/epidemiology EDAT- 2011/10/05 06:00 MHDA- 2012/01/14 06:00 CRDT- 2011/10/05 06:00 PHST- 2011/10/05 06:00 [entrez] PHST- 2011/10/05 06:00 [pubmed] PHST- 2012/01/14 06:00 [medline] AID - 10.3322/caac.20134 [doi] PST - ppublish SO - CA Cancer J Clin. 2011 Nov-Dec;61(6):409-18. doi: 10.3322/caac.20134. Epub 2011 Oct 3. PMID- 24716497 OWN - NLM STAT- MEDLINE DCOM- 20151023 LR - 20140410 IS - 1369-1627 (Electronic) IS - 0954-0261 (Linking) VI - 26 IP - 1 DP - 2014 Feb TI - A review of clinical aspects of breast cancer. PG - 4-15 LID - 10.3109/09540261.2013.852971 [doi] AB - Breast cancer is the most frequently diagnosed cancer in women and ranks second among causes for cancer related death in women. The ability to identify and diagnose breast cancer has improved markedly. Treatment decisions which were based in the past predominantly on the anatomic extent of the disease are shifting to the underlying biological mechanisms. Gene array technology has led to the recognition that breast cancer is a heterogeneous disease composed of different biological subtypes, and genetic profiling enables response to chemotherapy to be predicted. Breast conservation became an established standard of care and the oncoplastic approach enables wide excisions without compromising the natural shape of the breast. Sentinel lymph node biopsy has replaced axillary dissection as the standard procedure to stage the axilla and spared many patients the excess morbidity of axillary dissection. Targeted therapy to the oestrogen receptor plays a major role in systemic therapy; pathways responsible for endocrine resistance have been targeted as well. Biological therapy has been developed to target HER2 receptor and combination of antibody drug conjugates linked cytotoxic therapy to HER2 antibodies. Meaningful improvements in survival resulted from the new effective systemic agents and patients with metastasis are likely to have a longer survival. FAU - Libson, Shai AU - Libson S AD - Soroka Medical Centre, Ben Gurion University , Beer Sheva , Israel. FAU - Lippman, Marc AU - Lippman M LA - eng PT - Journal Article PT - Review PL - England TA - Int Rev Psychiatry JT - International review of psychiatry (Abingdon, England) JID - 8918131 SB - IM MH - Breast Neoplasms/diagnosis/*metabolism/*therapy MH - Female MH - Humans EDAT- 2014/04/11 06:00 MHDA- 2015/10/24 06:00 CRDT- 2014/04/11 06:00 PHST- 2014/04/11 06:00 [entrez] PHST- 2014/04/11 06:00 [pubmed] PHST- 2015/10/24 06:00 [medline] AID - 10.3109/09540261.2013.852971 [doi] PST - ppublish SO - Int Rev Psychiatry. 2014 Feb;26(1):4-15. doi: 10.3109/09540261.2013.852971. PMID- 26059925 OWN - NLM STAT- MEDLINE DCOM- 20151026 LR - 20161109 IS - 0065-2598 (Print) IS - 0065-2598 (Linking) VI - 862 DP - 2015 TI - Breast Cancer Survivorship: Where Are We Today? PG - 1-8 LID - 10.1007/978-3-319-16366-6_1 [doi] AB - Breast cancer is the most common cancer in women, and survivors with this diagnosis account for almost one fourth of the over 14 million cancer survivors in the US. After several decades of basic and clinical trials research, we have learned much about the heterogeneity of breast cancer and have evolved a complex and multidisciplinary treatment approach to the disease. Increasingly, we are paying attention to the long term and late effects of breast cancer treatment, and this is largely the subject of this volume. In this chapter, the authors introduce the topic of breast cancer survivorship and highlight the organization and content of this volume, briefly describing the contents of the subsequent chapters. FAU - Ganz, Patricia A AU - Ganz PA AD - UCLA Schools of Medicine and Public Health, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA, pganz@mednet.ucla.edu. FAU - Goodwin, Pamela J AU - Goodwin PJ LA - eng PT - Introductory Journal Article PL - United States TA - Adv Exp Med Biol JT - Advances in experimental medicine and biology JID - 0121103 SB - IM MH - Breast Neoplasms/genetics/*mortality/psychology/therapy MH - Female MH - Genetic Predisposition to Disease MH - Humans MH - Quality of Life MH - Survival Rate MH - *Survivors/psychology/statistics & numerical data MH - Syndrome MH - Treatment Outcome EDAT- 2015/06/11 06:00 MHDA- 2015/10/27 06:00 CRDT- 2015/06/11 06:00 PHST- 2015/06/11 06:00 [entrez] PHST- 2015/06/11 06:00 [pubmed] PHST- 2015/10/27 06:00 [medline] AID - 10.1007/978-3-319-16366-6_1 [doi] PST - ppublish SO - Adv Exp Med Biol. 2015;862:1-8. doi: 10.1007/978-3-319-16366-6_1. PMID- 26580154 OWN - NLM STAT- MEDLINE DCOM- 20151209 LR - 20151120 IS - 1476-4687 (Electronic) IS - 0028-0836 (Linking) VI - 527 IP - 7578 DP - 2015 Nov 19 TI - Breast cancer. PG - S101 LID - 10.1038/527S101a [doi] FAU - Woolston, Chris AU - Woolston C LA - eng PT - Introductory Journal Article PL - England TA - Nature JT - Nature JID - 0410462 SB - IM MH - Breast Neoplasms/*diagnosis/epidemiology/immunology/*therapy MH - Disease Susceptibility MH - Female MH - Humans MH - Mammography MH - Molecular Targeted Therapy MH - Risk Assessment EDAT- 2015/11/19 06:00 MHDA- 2015/12/15 06:00 CRDT- 2015/11/19 06:00 PHST- 2015/11/19 06:00 [entrez] PHST- 2015/11/19 06:00 [pubmed] PHST- 2015/12/15 06:00 [medline] AID - 527S101a [pii] AID - 10.1038/527S101a [doi] PST - ppublish SO - Nature. 2015 Nov 19;527(7578):S101. doi: 10.1038/527S101a. PMID- 28260181 OWN - NLM STAT- MEDLINE DCOM- 20180723 LR - 20181113 IS - 2038-3312 (Electronic) IS - 2038-131X (Linking) VI - 69 IP - 3 DP - 2017 Sep TI - Breast cancer in young women: an overview. PG - 313-317 LID - 10.1007/s13304-017-0424-1 [doi] AB - Despite dramatic advances in cancer research setting, breast cancer remains a major health problem and represents currently a top biomedical research priority. Worldwide, breast cancer is the most common cancer affecting women, and its incidence and mortality rates are expected to increase significantly the next years. Recently the researchers' interest has been attracted by breast cancer arising in young women. Current evidence suggests that in women aged <45 years, breast cancer is unquestionably the leading cause of cancer-related deaths. This type of cancer seems to be highly heterogeneous and has potentially aggressive and complex biological features. However, management strategies, recommendations and options are not age based and the 'complex' biology of this type of cancer remains uncertain and unexplored. In this review, we summarize the latest scientific information on breast cancer arising in young women highlighting the heterogeneity and the complex nature of this type of cancer. FAU - Anastasiadi, Zoi AU - Anastasiadi Z AD - Department of Surgery, School of Medicine, University of Ioannina, Ioannina, Greece. FAU - Lianos, Georgios D AU - Lianos GD AD - Department of Surgery, School of Medicine, University of Ioannina, Ioannina, Greece. georgiolianos@yahoo.gr. FAU - Ignatiadou, Eleftheria AU - Ignatiadou E AD - Department of Surgery, School of Medicine, University of Ioannina, Ioannina, Greece. FAU - Harissis, Haralampos V AU - Harissis HV AD - Department of Surgery, School of Medicine, University of Ioannina, Ioannina, Greece. FAU - Mitsis, Michail AU - Mitsis M AD - Department of Surgery, School of Medicine, University of Ioannina, Ioannina, Greece. LA - eng PT - Journal Article PT - Review DEP - 20170304 PL - Italy TA - Updates Surg JT - Updates in surgery JID - 101539818 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Age Factors MH - Biomarkers, Tumor/genetics MH - *Breast Neoplasms/diagnosis/genetics/mortality/pathology MH - Female MH - Humans MH - Young Adult OTO - NOTNLM OT - Breast cancer OT - Guidelines OT - Next-generation sequencing analyses OT - Personalized cancer medicine OT - Tumor heterogeneity OT - Young woman EDAT- 2017/03/06 06:00 MHDA- 2018/07/24 06:00 CRDT- 2017/03/06 06:00 PHST- 2016/10/30 00:00 [received] PHST- 2017/02/16 00:00 [accepted] PHST- 2017/03/06 06:00 [pubmed] PHST- 2018/07/24 06:00 [medline] PHST- 2017/03/06 06:00 [entrez] AID - 10.1007/s13304-017-0424-1 [pii] AID - 10.1007/s13304-017-0424-1 [doi] PST - ppublish SO - Updates Surg. 2017 Sep;69(3):313-317. doi: 10.1007/s13304-017-0424-1. Epub 2017 Mar 4.